The Goldman Sachs Group Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $27.00

Viridian Therapeutics (NASDAQ:VRDN) had its price objective reduced by The Goldman Sachs Group from $31.00 to $27.00 in a research report report published on Wednesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other analysts have also weighed in on VRDN. Royal Bank of Canada decreased their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a research report on Wednesday. Needham & Company LLC decreased their price objective on Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating on the stock in a report on Wednesday. JMP Securities dropped their target price on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $36.70.

Viridian Therapeutics Price Performance

Shares of VRDN stock opened at $12.54 on Wednesday. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $27.20. The company has a market capitalization of $1.02 billion, a P/E ratio of -2.91 and a beta of 0.57. The stock has a 50 day moving average of $13.71 and a two-hundred day moving average of $17.53. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. The firm’s revenue was up .0% compared to the same quarter last year. As a group, equities analysts expect that Viridian Therapeutics will post -4.03 EPS for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VRDN. Barclays PLC raised its holdings in shares of Viridian Therapeutics by 113.1% in the third quarter. Barclays PLC now owns 125,397 shares of the company’s stock valued at $2,851,000 after buying an additional 66,550 shares during the last quarter. JPMorgan Chase & Co. increased its position in Viridian Therapeutics by 218.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock valued at $9,108,000 after acquiring an additional 274,641 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of Viridian Therapeutics by 6.8% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 210,899 shares of the company’s stock worth $4,043,000 after purchasing an additional 13,498 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Viridian Therapeutics by 89.1% during the fourth quarter. SG Americas Securities LLC now owns 31,085 shares of the company’s stock worth $596,000 after purchasing an additional 14,644 shares in the last quarter. Finally, Moody Aldrich Partners LLC bought a new stake in shares of Viridian Therapeutics during the fourth quarter valued at approximately $1,125,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.